Protein biomarker discovery & development

Accelerating Biomarker Research Through Robust Immuno-based Proteomics

Reliable biomarkers are essential for  early disease detection, patient stratification, and treatment monitoring. Among biomarker types, proteins offer significant advantages, enabling cost-efficient and high-throughput measurements often within minutes using standard immuno-assays or lateral flow devices. Sciomics is a leading Biomarker CRO dedicated to advancing protein biomarker research for precison medicine. We provide a comprehensive and reproducible approach to biomarker discovery and validation utilizing our scioDiscover platform. Our expertise assists researchers across diverse fields, ensuring the generation of robust and clinically relevant results.

Enabling reliable & translational Biomarker Discovery

Our scioDiscover platform ensures:

  • Robust Data: Ensure data reliability and high reproducibility with four technical replicates per target protein and sample.
  • Broad Coverage: Unmatched multiplexing and sensitivity for diverse, complex samples.
  • Effortless translation: Seamless integration into diagnostic assays and lab tests due to immuno-based methodology..
With these benefits, Sciomics is your ideal partner for biomarker discovery and development.
Sciomics supports the discovery and development of a variety of different protein biomarker types such as drug response markers, stratification markers, CDx markers, prognostic biomarkers or diagnostic biomarkers.

Our track record in biomarker discovery

We have performed successful biomarker studies in diverse research areas, including:

  • Acute Kidney Injury (AKI)
  • Assessing Dengue Fever Severity
  • Neurodegenerative Diseases (Alzheimer’s & Parkinson’s)
  • MCDS (Metaphyseal Chondrodysplasia, Schmid Type)
  • COVID-19 disease severity
  • Endometrial Cancer
  • Endometriosis
  • Infectious Diseases

      Learn about
  these projects    

Comprehensive Scientific Support for Protein Biomarker Discovery & Development

 We offer tailored expert guidance throughout the entire process, from study design and protein analysis to data interpretation and biomarker validation. Choose Sciomics as your preferred Biomarker CRO for development projects. 

Sciomics supports your protein biomarker development project via the steps study design, sample selection, sample analysis, data analysis, data interpretation as well as validation.

1. Study design:  Our experts help perfect your experimental biomarker study setup, sample, and control selection for robust, meaningful results.

2. Sample selection: We analyze diverse sample types (plasma, serum, urine, CSF, ISF, PBMC, tissue, cells, etc.), requiring minimal input amounts.

3. Sample analysis: Our experts process your samples from protein extraction to incubation, delivering results quickly (within few weeks).

4. Data analysis: Comprehensive bioinformatics and machine learning provide actionable insights, ROC-curves, and robust, interpretable biomarker panels for routine testing.

5. Data interpretation: Detailed reports and guidance to support your validation and follow-up strategies.

6. Validation:  Our antibody platform facilitates easy transfer to standard immuno-assays, accelerating validation and diagnostic assay development. 

 

Biomarker discovery based on our antibody-based discovery platform ensures a straight-forward translation into other immuno-assays for validation, accelerating and de-risking the development of diagnostic assays. 

 

      Discuss your project
  with a scientist    

 

Validating scioDiscover Biomarkers: Proven Success

Direct Validation: Easily confirm scioDiscover findings using common immuno-assays like ELISA.

Accelerated Implementation: Speed up the journey from biomarker discovery to clinical use and diagnostics.

Exceptional Correlation: Strong agreement (Pearson’s r > 0.9) between discovery and validation data.

 

Correlation of r > 0.9 for data generated by the scioDiscover platform and biomarker measurement in a routine clinical laboratory

An immunobased discovery approach for protein biomarkers enables an easy translation to other immunobased platforms such as ELISA for validation.

 

Selected projects with external validation

Roche: Validated two biomarkers using their Elecsys platform ( poster)

AbbVie: Confirmed biomarkers from a small cohort on an internal platform (paper)

University Hospital Heidelberg: Validated CRP in their clinical laboratory; additional marker confirmed by ELISA in our lab (paper)

Hannover Medical School: Validation of tissue proteomics/phosphoproteomics in a mouse model by Western Blotting (paper)

Charité: Verified phosphorylation state via Western blot/IHC in a tissue study (paper)

Scientific articles utilizing scioDiscover

Article | Fimepinostat Targets HDAC2 to Suppress Schwannoma Growth

| March 2026 | The HDAC inhibitor fimepinostat effectively induces apoptosis and suppresses tumor cell proliferation, highlighting its potential as a therapeutic strategy for schwannoma.
Sciomics supported the study with proteomic profiling and post-translational modification analysis of human cell samples.

Nagel et al., Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636  

Article | Parkinson’s Striatum Organoids Show Increased Inflammation Hallmarks

| February 2026 | Patient-derived striatum organoids carrying the LRRK2-G2019S mutation reveal early Parkinson’s Disease features, including neuroinflammation and altered signalling. Sciomics supported the study by analysing patient-derived striatum organoids using the scioDiscover proteomic microarray.

Barmpa et al., Parkinson’s Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation. Mov Disord. (2026), published online February 11, 2026  

Article | Fos-induced Osteosarcoma Links Cachexia-like Wasting to FGF21

| February 2026 | Fos-driven osteosarcoma induces systemic metabolic alterations and identified FGF21 as a key mediator and promising biomarker of cancer-associated cachexia. Sciomics supported the study by analysing murine serum samples using the scioDiscover proteomic microarray.

Luther et al., Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. Cancer Metab. (2026)  

Article | Lactate-driven immune hotspots resolved via SLC5A12 blockade

| August 2025 | Lactate signaling induces cytokine production and T/B cell clustering in Sjögren’s disease, and SLC5A12 blockade reverses these effects. Sciomics contributed to this study by comparing protein abundance and acetylation levels of murine cells using the scioDiscover protein profiling platform.

Certo, M, et al.. Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution. Nat Metab. 2025;7(8):1663-1680.  

Article | ECM stabilisation drives rapamycin‑mediated lifespan extension in Marfan mgR/mgR mice

| May 2025 | Rapamycin extends lifespan in a Marfan syndrome mouse model by stabilising the extracellular matrix via increased ECM protein expression. Sciomics supported this study by identifying differentially expressed proteins in rapamycin-treated mice using the scioDiscover microarray platform.

Zaradzki et al., Stabilisation of extracellular matrix is crucial to rapamycin-mediated life span increase in Marfan mgR/mgR mice. Biochem Pharmacol. 2025;235:116830  

What clients say about scioDiscover

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Anke König

Clinics for dermatology, venerology and allergology, University Clinics Frankfurt, Frankfurt, Germany

"We enjoyed working with Sciomics on various research projects related to inflammatory skin diseases. The cooperation with Sciomics was just excellent. In addition to processing the samples and compiling the data in a perfectly understandable way, Sciomics GmbH supports us with the entire interpretation and presentation of our results with lots of ideas beyond the usual level of corporate performance. We are looking forward to developing new ideas for further clinical studies together."

Product: scioDiscover

 

 

José Pedro Castro, PhD

German Instiute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany

"I am more than pleased to recommend Sciomics Antibody Microarray analysis service. We used it to compare differentiating from non-differentiating cells and it was a precious help which allowed us to understand the different phenotypes. The results were sent fast and ready to publish ! Their availability to clarify doubts was simply outstanding. Christoph, Ronny and their team are well prepared to assist in designing the experiments in order to get the maximum of the array. If I hit a road block in my experiments, I am sure that their services will help me go through."

Product: scioDiscover protein profiling service

BACK_TO_TOP